13，Barlogie B,Smith L,Alexanian R.Effective treatment of advanced multiple meyloma refractory to alkylating agents. N Engl J Med,1984,310:1353
26，Paul A J.Plasma and cellular adriamycin concentrations in patients with myeloma treated with ninth-six-hour continuous infusion.Clin Pharmacol Ther,1987,41:661
37，Westin J, Rodjer S,Turesson I,et al.Interferon alfa-2b versus no maintenance during the plateau in multiple myeloma:a randomized study.Br J Haematol,1995,89:561
5Blade J, Samson D, Reeee D, et al. Cri- teria for evaluating disease response and progression in patients with multiple my- eloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant [J]. Br J Haematol, 1998,102 (5):1115-1123.
6Zervas K, Mihou D, Katodritou E, et al.VAD-doxil versus VAD-doxil plus thal- idomide as initial treatment for multiple myeloma: results ofa multicenter randomi- ,zed trial of the Greek Myeloma Study Group [J]. Ann Oncol, 2007,18(8):1369- 1375.
7Chanan-Khan AA, Lee K. Pegylated lipo- somal doxorubicin and immunomodul- atory drug combinations in multiple myel- oma: rationale and clinical experience [J]. Clin Lymphoma Myeloma, 2007,7(Suppl 4):$163-169.
8Baz R, Walker E, Karam MA, et al.Len- alidomide and pegylated liposomal dox- orubicin based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy [J]. Ann Oncol, 2006,17(12): 1766-1771.
9Offidani M, Corvatta L, Piersantelli MN, et al. Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma [J]. Blood, 2006,108(7):2159-2164.
